To Err is Human …

Authors

  • S. Rádl Zentiva Co, Prague

Keywords:

ONC201, patent protection, clinical studies, isomer mismatch, analytical control

Abstract

The compound originally known as TIC10 or ONC201 is a new anticancer drug developed by Oncoceutics, Inc. The agent's Investigational New Drug Application for phase I/II clinical studies has been recently approved by Food & Drug Administration. However, a Scripp Institute's group revealed that the compound structure given in all documents, including patents, was erroneous and applied for a patent protection for the correct structure. Chemistry backgrounds associated with this case is reviewed together with the relevant consequences regarding the intellectual property issue.

Downloads

Published

2015-01-15

How to Cite

Rádl, S. (2015). To Err is Human …. Chemické Listy, 109(1), 3–6. Retrieved from http://w.chemicke-listy.cz/ojs3/index.php/chemicke-listy/article/view/406

Issue

Vol. 109 No. 1 (2015)

Section

Articles